Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Autor: Lowenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B.J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L.W., Jongen-Lavrencic, M., Kooy, M.V., Vekemans, M.C., Velden, W.J.F.M. van der, Beverloo, B., Michaux, L., Graux, C., Deeren, D., Weerdt, O. de, Esser, J.W.J. van, Bargetzi, M., Klein, S.K., Gadisseur, A., Westerweel, P.E., Veelken, H., Gregor, M., Silzle, T., Lammeren-Venema, D. van, Moors, I., Breems, D.A., Hoogendoorn, M., Legdeur, M.C.J.C., Fischer, T., Kuball, J., Cornelissen, J., Porkka, K., Juliusson, G., Meyer, P., Hoglund, M., Gjertsen, B.T., Janssen, J.J.W.M., Huls, G., Passweg, J., Cloos, J., Valk, P.J.M., Elssen, C.H.M.J. van, Manz, M.G., Floisand, Y., Ossenkoppele, G.J., Dutch-Belgian Hemato-Oncology Coop, Swiss Grp Clinical Canc Res SAKK

Publikováno v: Blood Adv
Blood advances, 5(4), 1110-1121. American Society of Hematology
Blood advances
Blood, 5(4), 1110-1121. American Society of Hematology
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855
BLOOD ADVANCES
Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood Advances, 5, 1110-1121
Blood advances, 5(4), 1110-1121. The American Society of Hematology
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood Advances, 5, 4, pp. 1110-1121
Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b667f8652f65ff1c599befd9584961
https://pubmed.ncbi.nlm.nih.gov/33616652

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

Autor: Young, E, Noerenberg, D, Mansouri, L, Ljungström, V, Frick, M, Sutton, L-A, Blakemore, SJ, Galan-Sousa, J, Plevova, K, Baliakas, P, Rossi, D, Clifford, R, Roos-Weil, D, Navrkalova, V, Dörken, B, Schmitt, CA, Smedby, KE, Juliusson, G, Giacopelli, B, Blachly, JS, Belessi, C, Panagiotidis, P, Chiorazzi, N, Davi, F, Langerak, AW, Oscier, D, Schuh, A, Gaidano, G, Ghia, P, Xu, W, Fan, L, Bernard, OA, Nguyen-Khac, F, Rassenti, L, Li, J, Kipps, TJ, Stamatopoulos, K, Pospisilova, S, Zenz, T, Oakes, CC, Strefford, JC, Rosenquist, R, Damm, F

Publikováno v: Sygma
Institutional Repository for Molecular Medicine (MDC)
Leukemia, 31(7), 1547-1554. Nature Publishing Group
Leukemia, vol 31, iss 7

Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hots

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::68e8440f22f726f4a7ad0c11d529803d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

Autor: Young, E. Noerenberg, D. Mansouri, L. Ljungström, V. Frick, M. Sutton, L.-A. Blakemore, S.J. Galan-Sousa, J. Plevova, K. Baliakas, P. Rossi, D. Clifford, R. Roos-Weil, D. Navrkalova, V. Dörken, B. Schmitt, C.A. Smedby, K.E. Juliusson, G. Giacopelli, B. Blachly, J.S. Belessi, C. Panagiotidis, P. Chiorazzi, N. Davi, F. Langerak, A.W. Oscier, D. Schuh, A. Gaidano, G. Ghia, P. Xu, W. Fan, L. Bernard, O.A. Nguyen-Khac, F. Rassenti, L. Li, J. Kipps, T.J. Stamatopoulos, K. Pospisilova, S. Zenz, T. Oakes, C.C. Strefford, J.C. Rosenquist, R. Damm, F.

Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hots

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::8a1f09dcc6f090a2d6237af030848cb8
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3085766